Roche reports positive data from chronic lymphocytic leukaemia drug trial

Roche has announced new clinical trial data that demonstrates the benefits offered by a new combination treatment for chronic lymphocytic leukaemia.

Data from the phase III MURANO study has demonstrated the effectiveness of Venclexta/Venclyxto plus MabThera/Rituxan in the treatment of relapsed or refractory chronic lymphocytic leukaemia, with a total of 389 patients involved in the trial.

The combination regimen met its primary endpoint by showing a statistically significant improvement in progression-free survival compared to bendamustine plus MabThera/Rituxan, while no new safety signals were observed.

Venclexta/Venclyxto is being developed by AbbVie and Roche and will be jointly commercialised by AbbVie and Roche subsidiary Genentech in the US, with AbbVie handling international sales on its own.

Dr Sandra Horning, Roche's chief medical officer and head of global product development, said: "We will work with health authorities to bring this potential chemotherapy-free treatment option to the people who need it as quickly as possible."

Data from the MURANO study will be presented at an upcoming medical meeting and submitted to regulators to support future approvals for this regimen.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.